Goldman Sachs
BCYC

Goldman Sachs’s Bicycle Therapeutics BCYC Stock Holding History

Goldman Sachs’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$511K Buy
110,147
+85,415
+345% +$488K ﹤0.01% 5581
2025
Q4 		$175K Buy
+24,732
New +$182K ﹤0.01% 6073
2025
Q3 		– Sell
-52,265
Closed -$363K – 6339
2025
Q2 		$363K Buy
52,265
+27,073
+107% +$216K ﹤0.01% 5346
2025
Q1 		$214K Buy
+25,192
New +$297K ﹤0.01% 5611
2024
Q3 		– Sell
-13,907
Closed -$281K – 5816
2024
Q2 		$281K Sell
13,907
-41,543
-75% -$939K ﹤0.01% 5135
2024
Q1 		$1.38M Buy
+55,450
New +$1.18M ﹤0.01% 4122
2023
Q3 		– Sell
-18,215
Closed -$465K – 5539
2023
Q2 		$465K Buy
18,215
+7,667
+73% +$178K ﹤0.01% 4787
2023
Q1 		$224K Sell
10,548
-70,005
-87% -$1.76M ﹤0.01% 5246
2022
Q4 		$2.38M Sell
80,553
-24,738
-23% -$664K ﹤0.01% 3811
2022
Q3 		$2.45M Sell
105,291
-49,035
-32% -$1.17M ﹤0.01% 3811
2022
Q2 		$2.59M Sell
154,326
-8,939
-5% -$189K ﹤0.01% 3820
2022
Q1 		$7.16M Buy
163,265
+142,578
+689% +$6.66M ﹤0.01% 3008
2021
Q4 		$1.26M Buy
20,687
+5,824
+39% +$321K ﹤0.01% 4645
2021
Q3 		$618K Buy
+14,863
New +$520K ﹤0.01% 5070

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's BCYC Position: Q1 2026 in Review

Goldman Sachs increased its Bicycle Therapeutics (BCYC) stake by 345% in Q1 2026, buying an estimated $488K and bringing the position to 110,147 shares worth $511K. The position accounts for ﹤0.01% of the portfolio, ranked #5581.

Goldman Sachs first reported a position in BCYC in Q3 2021 and has held it in 14 quarters since. The position peaked at $7.16M in Q1 2022. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • Goldman Sachs held 110,147 shares of Bicycle Therapeutics worth $511K as of Q1 2026.
  • Goldman Sachs bought 85,415 Bicycle Therapeutics shares in Q1 2026, an estimated $488K.
  • Bicycle Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5581 holding.
  • Goldman Sachs first reported a position in Bicycle Therapeutics in Q3 2021 and has held it in 14 quarters since.
  • Goldman Sachs's Bicycle Therapeutics position peaked at $7.16M in Q1 2022.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.